Enhancing First-Line IBD Treatment with CurQD®
The world's top medical centers ensure their treatment incorporates the latest and best science offers. Years of high-quality research and successful clinical trials have positioned CurQD® by Evinature at the cutting edge of adjunct IBD therapy, with consistent and considerable success in improving first-line treatment and managing Crohn’s Disease and Ulcerative Colitis.
Trusted and Recognised by Gastroenterologists

"I first started using CurQD® on a whim for very refractory patients. Much to my surprise I had good results. Now I incorporate it much more in caring for my Ibd patients who are receptive to using this agent as it doesn’t not suppress their immune system. For some patients it’s a game changer."
Dr Jim George

"Now we have great data to suggest that CurQD is a promising option for our patients who are flaring despite being on 5ASA and who are not quite ready for stepping up to a biologic or small molecule."
Maia Kayal
CurQD®: Revolutionizing IBD Treatment
CurQD® is the flagship nutraceutical protocol produced by Evinature™. Combining two clinically proven nutraceuticals, an NF-kappaB inhibitor and an AhR agonist, CurQD® has shown high efficacy in inducing clinical and endoscopic remission in active IBD, CurQD® demonstrates high rates of success when combined as an add-on to first-line drug therapy.

*Significant endoscopic response was observed in 75% of patients on CurQD® at week 8.
Explore the Clinical Trials
- Published in Clinical Gastroenterology and Hepatology, a randomized, double-blind, placebo-controlled clinical trial conducted in patients with active UC:
- Clinical Remission was achieved in 50% of patients receiving CurQD® at the end of the 8-week induction period.
- Significant endoscopic response was observed in 75% of patients on CurQD® at week 8.
- Published in Alimentary Pharmacology and Therapeutics, a retrospective study in moderate-severe, treatment-refractory, ulcerative colitis patients, CurQD® adjunct therapy showed:
- Patients previously treated with biologics or small molecules, 39.5% achieved clinical remission and 58.1% showed a clinical response,after 8-12 weeks treatment.
- In a retrospective study in Crohn’s disease, patients with active Crohn’s received adjunct treatment with CurQD® for 8-12 weeks. At the end of induction:
- Clinical Remission: Achieved in 52% of patients at the end of induction.
- Biomarker Remission: Observed in 53% of patients at the end of induction.
Meet the Founders a Crohn's and Colitis Congress
The Evinature Founders will be present at the CCC held in San Francisco this year. Visit the poster exhibition for two studies on CurQD presented by physicians from Mt. Sinai and iCare center in Prague to learn more about CurQD. Nir Solomon, Co-Founder of Evinature, and Apan (Amos) Damri, CEO of Evinature, will be there to answer questions. If you would like to hear more about Evinature and CurQD, please reach out using the contact form below and we will be in touch!

Nir Salomon (C.Ac, C.Hb)
Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center & co-founder and acting CEO of the Sino-Israeli Research Foundation (SIRF).

Prof. Shomron Ben-Horin M.D.
Chief Gastroenterology Department & Director, the Gastro-Immunology Research Laboratory Department of Gastroenterology Sheba Medical Center, Tel-Hashomer.
Read More from What Doctors Are Saying

“CurQD offers a novel approach to the management of IBD and, whether alone or in combination with other therapies, has been an exciting option for our patients, who love the idea of a therapy like this,” states
David T. Rubin, MD

"We presented our local experience using CurQD® as an adjunct treatment to standard therapy in our pediatric patient population with IBD. We were impressed to note that most patients experienced not only symptomatic improvement after starting CurQD®, but also had objective findings of improvement, such as biochemical markers and/or intestinal ultrasound.”
Dr. Mallory Chavannes
The Essense of CurQD
CurQD® is a cutting edge adjunct IBD therapy that addresses patients’ symptoms at the source to provide improved patient outcomes and remission. Our protocols, based in the highest-quality research and clinical trials, demonstrate reduced symptoms and severity of IBD, and improve sustained remission through ongoing adherence to evidence-backed data.
Sign Up
Stay informed with the latest trials, treatments & fresh arrivals:
- Choosing a selection results in a full page refresh.
- Opens in a new window.